PDA

View Full Version : New Data Presented From EMBLEMô Study For Pipeline Drug Epratuzumab For Patients Suff



RSS Bot
06-17-2010, 05:11 AM
UCB (Euronext: UCB) and Immunomedics, Inc. (Nasdaq: IMMU) announced new lupus drug candidate, epratuzumab, provided a significant reduction in disease activity in patients with moderate to severe active systemic lupus erythematosus (SLE)...

More... (http://mnt.to/f/3DZ9)